In this interview Kenny Green, Edison’s Israel director, and Russ Putland, Lavie Bio’s VP Commercial, discuss Lavie Bio’s recent announcement and new product launch of its inoculant (bio-stimulant) Result.
Lavie Bio is a subsidiary of Evogene (EVGN, market cap US$112m), which is listed on Nasdaq and the Tel Aviv Stock Exchange. Lavie Bio’s goal is to improve food quality, health and agricultural sustainability through introducing microbiome-based agricultural-biological products.
This video contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates”, or words of similar meaning. For example, Evogene and Lavie Bio are using forward-looking statements in this press release when they discuss Lavie Bio’s pipeline and commercialization plans, including future opportunities and territories, and the potential benefits of LAV.211/Result. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, and involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene’s reports filed with the applicable securities authorities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.